alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 301–325 of 354 studies published 2016 · free to read (page 13 of 15) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 354 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Therapies for Prevention and Treatment of Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. BioMed research international 2016-07-28

Alzheimer's disease (AD) is the most common cause of dementia associated with a progressive neurodegenerative disorder, with a prevalence of 44 million people throughout the world in 2015, and this figure is estimated to double by 2050. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Drug treatments in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Clinical medicine (London, England) 2016-06-01

Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease (AD) and these act to control symptoms rather than alter the course of the disease. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Defining the spectrum of frontotemporal dementias associated with TARDBP mutations

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurology. Genetics 2016-05-26

We describe the largest series of patients with TARDBP mutations presenting with frontotemporal dementia (FTD) and review the cases in the literature to precisely characterize FTD diseases associated with this genotype. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Cellular and molecular neurobiology 2016-02-22

There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-β accumulation or brain atrophy. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in molecular neuroscience 2016-07-08

We propose that brain energy deficit is an important pre-symptomatic feature of Alzheimer's disease (AD) that requires closer attention in the development of AD therapeutics. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Nuclear but not mitochondrial-encoded oxidative phosphorylation genes are altered in aging, mild cognitive impairment, and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2016-10-25

Our findings suggest that restoration of the expression of nuclear-encoded OXPHOS genes in aging could be a viable strategy for blunting AD progression. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric Disorders

✓ Peer-reviewed alzhub usefulness score 43 out of 100. International neurourology journal 2016-05-26

Brain diseases and disorders such as Alzheimer disease, Parkinson disease, depression, schizophrenia, autism, and addiction lead to reduced quality of daily life through abnormal thoughts, perceptions, emotional states, and behavior. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Acta neuropathologica communications 2016-02-25

The hTau40(AT) mice mimic pathological hallmarks of tauopathies including a cognitive phenotype combined with pronounced neuroinflammation visible by bioluminescence. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?

✓ Peer-reviewed alzhub usefulness score 42 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2016-01-14

Antidepressants have modest efficacy in late-life depression (LLD), perhaps because various neurobiologic processes compromise frontolimbic networks required for antidepressant response. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Olfaction in People with Down Syndrome: A Comprehensive Assessment across Four Decades of Age

✓ Peer-reviewed alzhub usefulness score 42 out of 100. PloS one 2016-01-05

However, specificity of this olfactory profile to DS should be considered with some caution because cognition was not evaluated in all DS participants and comparison with a control group of non-DS individuals having cognitive disabilities was lacking. 1 key finding →

Participants: 56 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Differentiation of Amnestic Type MCI from the Non-Amnestic Types by Structural MRI

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Frontiers in aging neuroscience 2016-03-30

The amnestic mild cognitive impairment/non-amnestic mild cognitive impairment separation is not only theoretical but backed by structural imaging methods and neuropsychological tests. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Current Alzheimer research 2016-01-01

Long-non-coding RNAs (lncRNAs), RNA molecules longer than 200 nucleotides, have been involved in several biological processes and in a growing number of diseases, controlling gene transcription, pre-mRNA processing, the transport of mature mRNAs to specific cellular compartments, the regulation of mRNA stability, protein translation and turnover. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2016-02-26

Positron emission tomography (PET) imaging of brain amyloid beta is now clinically available in several countries including the United States and the United Kingdom, but not Canada. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Communication Bridge: A pilot feasibility study of Internet-based speech-language therapy for individuals with progressive aphasia

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's & dementia (New York, N. Y.) 2016-11-01

Internet-based SLT using person-centered interventions provides a feasible model for delivering care to individuals with dementia and mild/moderate aphasia symptoms who have an engaged care-partner and prior familiarity with a computer. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed